6533b859fe1ef96bd12b79c6

RESEARCH PRODUCT

Impact of Chemotherapy in the Adjuvant Setting of Early Stage Uterine Leiomyosarcoma: A Systematic Review and Updated Meta-Analysis

Lorena IncorvaiaValerio Di ScioscioMargherita NanniniValentina IndioAnna Myriam PerroneAnnalisa AstolfiAntonio De LeoMaria Abbondanza PantaleoAlessandro RizzoPierandrea De Iaco

subject

OncologyCancer Researchmedicine.medical_specialtyuterine sarcomamedicine.medical_treatmentchemotherapylcsh:RC254-282meta-analysiArticleNOuterine leiomyosarcoma03 medical and health sciences0302 clinical medicineInternal medicinemedicineAdjuvant therapy030212 general & internal medicineStage (cooking)meta-analysis uterine leiomyosarcoma uterine sarcoma adjuvant therapy chemotherapyUterine sarcomabusiness.industryadjuvant therapyOdds ratiomedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensConfidence intervalClinical trialRadiation therapymeta-analysisadjuvant therapy chemotherapyOncology030220 oncology & carcinogenesisMeta-analysisAdjuvant therapy Uterine sarcoma Uterine leiomyosarcoma Meta-analysis Chemotherapybusiness

description

Background: Although the use of adjuvant chemotherapy (AC) appears to be increasing over the past few years, several clinical trials and previous meta-analyses failed to determine whether AC could improve clinical outcomes in uterine leiomyosarcoma (uLMS). The aim of this systematic review and meta-analysis was to compare AC (with or without radiotherapy) versus observation (obs) after primary surgery in early stage uLMS. Materials and Methods: Randomized controlled (RCTs) and non-randomized studies (NRSs) were retrieved. Outcomes of interest were as follows: distant recurrence rate, locoregional recurrence rate and overall recurrence rate. Results about distant recurrence rate, locoregional recurrence rate and overall recurrence rate were compared by calculating odds ratios (ORs) with 95% confidence intervals (CIs)

10.3390/cancers12071899https://www.mdpi.com/2072-6694/12/7/1899